RJFSA
RXRX icon

Raymond James Financial Services Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$444K Sell
67,401
-22,579
-25% -$162K ﹤0.01% 2707
2024
Q2 		$675K Buy
89,980
+25,046
+39% +$218K ﹤0.01% 2333
2024
Q1 		$647K Buy
+64,934
New +$723K ﹤0.01% 2334

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Raymond James Financial Services Advisors's RXRX Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 25% in Q3 2024, selling an estimated $162K and leaving 67,401 shares worth $444K. The position accounts for ﹤0.01% of the portfolio, ranked #2707.

Raymond James Financial Services Advisors first reported a position in RXRX in Q1 2024 and has held it in 3 quarters since. The position peaked at $675K in Q2 2024. 267 funds tracked by Wall St. Rank hold RXRX as of Q3 2024.

  • Raymond James Financial Services Advisors held 67,401 shares of Recursion Pharmaceuticals worth $444K as of Q3 2024.
  • Raymond James Financial Services Advisors sold 22,579 Recursion Pharmaceuticals shares in Q3 2024, an estimated $162K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2707 holding.
  • Raymond James Financial Services Advisors first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • Raymond James Financial Services Advisors's Recursion Pharmaceuticals position peaked at $675K in Q2 2024.
  • 267 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.